Press Announcements > FDA approves new treatment for moderately to severely active ulcerative colitis

Press Announcements > FDA approves new treatment for moderately to severely active ulcerative colitis

	FDA approves new treatment for moderately to severely active ulcerative colitis

The U.S. Food and Drug Administration today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis. Xeljanz is the first oral medication approved for chronic use in this indication. Other FDA-approved treatments for the chronic treatment of moderately to severely active ulcerative colitis must be administered through an intravenous infusion or subcutaneous injection. Continue reading...